Peripherally restricted CB1 receptor antagonist:research advances / 国际药学研究杂志

ABSTRACT

Cannabinoid 1 receptor (CB1R) is one of most important targets for the treatment of obesity. However, the clinical application of CB1R antagonist rimonabant is restricted because of the central nervous system-related unwanted liabilities. Peripherally restricted CB1R antagonist with limited blood-brain-barrier penetration may maintain the antiobesity efficacy of rimonabant without unwanted side effects. This strategy has become the new hot spot for the development of antiobesity drugs. In this paper, we review the recent progress in peripherally restricted CB1 receptor antagonist .